Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s Enhertu Beats Kadcyla in 2nd-Line Breast Cancer
August 11, 2021
- Meiji Distributing AstraZeneca’s COVID-19 Vaccine in Japan
August 11, 2021
- Healios Bolsters Capital Alliance with Athersys, Gets Manufacturing License for Cell Therapy Product
August 10, 2021
- Vitrakvi Oral Solution Now Available in Japan: Bayer
August 10, 2021
- Pfizer Japan Announces Shipment Curbs, Stockouts for 9 Products in Knock-On Effect
August 10, 2021
- Otsuka’s 4 Global Brands Likely to Hit 480 Billion Yen, 2 Years Earlier
August 10, 2021
- HIF-PH Drugs’ Sluggish Q1 Sales Signal Tepid Uptake as Side Effect Concerns Weigh
August 10, 2021
- Foreign Drug Makers Scrapping Sales Offices as Sanofi Follows GSK, Novartis, AZ
August 6, 2021
- Kissei Sublicenses Fostamatinib to Chinese Firm
August 6, 2021
- Mitsubishi Tanabe’s NMOSD Drug Approved in South Korea
August 6, 2021
- Opdivo Snatches Back Top Spot in Japan Drug Ranking in July: Encise
August 6, 2021
- Kyowa Kirin Licenses Dutch Biotech’s ADC Technology
August 6, 2021
- Ono Collaborates with UK’s AI Specialty Pharma on Drug Discovery
August 6, 2021
- Daiichi Sankyo Gets Rights to HISHOH's Immunostimulating Agent for Sublingual Immunotherapies
August 5, 2021
- Canaglu Filed for CKD in Type 2 Diabetes: Mitsubishi Tanabe
August 5, 2021
- Mitsubishi Tanabe’s Spinal Cord Injury Drug Gets Fast-Track Tag in US
August 5, 2021
- Mitsubishi Tanabe Yields 3.9% Sales Increase in Q1 on Radicava’s Overseas Growth
August 5, 2021
- Eisai’s Q1 Sales Jump 20% on Growth of 4 Global Brands
August 5, 2021
- Kyowa Kirin’s H1 Sales Grow 4.6% on Brisk Global Products
August 4, 2021
- Kyosomirai, Nissin Roll Out Cymbalta Generics
August 4, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…